Boxed Warning of HBV Risk Added to Rituxan, Arezerra MedPage Today The FDA announced today that rituximab (Rituxan) and ofatumumab (Arzerra) will now carry a boxed warning of the risk for immunosuppression-related reactivation of hepatitis B virus (HBV). The two agents are anti-CD20-directed monoclonal antibodies ... Hepatitis B Reactivation Prompts New Warnings for Arzerra, Rituxan |
